ATE369372T1 - 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen - Google Patents

42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen

Info

Publication number
ATE369372T1
ATE369372T1 AT04810769T AT04810769T ATE369372T1 AT E369372 T1 ATE369372 T1 AT E369372T1 AT 04810769 T AT04810769 T AT 04810769T AT 04810769 T AT04810769 T AT 04810769T AT E369372 T1 ATE369372 T1 AT E369372T1
Authority
AT
Austria
Prior art keywords
derivatives
alkoxyalkylrapamycine
compositions containing
containing same
alkoxyalkyl
Prior art date
Application number
AT04810769T
Other languages
English (en)
Inventor
Ronald Betts
Douglas Savage
John Shulze
Original Assignee
Sun Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Biomedical Ltd filed Critical Sun Biomedical Ltd
Application granted granted Critical
Publication of ATE369372T1 publication Critical patent/ATE369372T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
AT04810769T 2003-11-12 2004-11-12 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen ATE369372T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/706,055 US7220755B2 (en) 2003-11-12 2003-11-12 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same

Publications (1)

Publication Number Publication Date
ATE369372T1 true ATE369372T1 (de) 2007-08-15

Family

ID=34552458

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04810769T ATE369372T1 (de) 2003-11-12 2004-11-12 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen

Country Status (6)

Country Link
US (2) US7220755B2 (de)
EP (2) EP1852437B1 (de)
AT (1) ATE369372T1 (de)
DE (1) DE602004008105T2 (de)
ES (1) ES2516692T3 (de)
WO (1) WO2005047295A1 (de)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
GB0121980D0 (en) 2001-09-11 2001-10-31 Cathnet Science Holding As Expandable stent
US20030135266A1 (en) 2001-12-03 2003-07-17 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7147656B2 (en) 2001-12-03 2006-12-12 Xtent, Inc. Apparatus and methods for delivery of braided prostheses
US8080048B2 (en) 2001-12-03 2011-12-20 Xtent, Inc. Stent delivery for bifurcated vessels
US7137993B2 (en) 2001-12-03 2006-11-21 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7182779B2 (en) 2001-12-03 2007-02-27 Xtent, Inc. Apparatus and methods for positioning prostheses for deployment from a catheter
US7309350B2 (en) 2001-12-03 2007-12-18 Xtent, Inc. Apparatus and methods for deployment of vascular prostheses
US7351255B2 (en) 2001-12-03 2008-04-01 Xtent, Inc. Stent delivery apparatus and method
US20040186551A1 (en) 2003-01-17 2004-09-23 Xtent, Inc. Multiple independent nested stent structures and methods for their preparation and deployment
US7892273B2 (en) 2001-12-03 2011-02-22 Xtent, Inc. Custom length stent apparatus
US7294146B2 (en) 2001-12-03 2007-11-13 Xtent, Inc. Apparatus and methods for delivery of variable length stents
US7084153B2 (en) * 2002-04-12 2006-08-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic
US7241308B2 (en) * 2003-06-09 2007-07-10 Xtent, Inc. Stent deployment systems and methods
US7553324B2 (en) * 2003-10-14 2009-06-30 Xtent, Inc. Fixed stent delivery devices and methods
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US7326236B2 (en) 2003-12-23 2008-02-05 Xtent, Inc. Devices and methods for controlling and indicating the length of an interventional element
ATE418559T1 (de) * 2004-03-01 2009-01-15 Terumo Corp Verfahren zur herstellung von o-alkylierten rapamycinderivaten
US7323006B2 (en) 2004-03-30 2008-01-29 Xtent, Inc. Rapid exchange interventional devices and methods
US20050288766A1 (en) 2004-06-28 2005-12-29 Xtent, Inc. Devices and methods for controlling expandable prostheses during deployment
US8317859B2 (en) 2004-06-28 2012-11-27 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US20060034884A1 (en) * 2004-08-10 2006-02-16 Stenzel Eric B Coated medical device having an increased coating surface area
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US8221824B2 (en) * 2005-02-03 2012-07-17 Boston Scientific Scimed, Inc. Deforming surface of drug eluting coating to alter drug release profile of a medical device
US7402168B2 (en) * 2005-04-11 2008-07-22 Xtent, Inc. Custom-length stent delivery system with independently operable expansion elements
WO2007011707A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
WO2007109621A2 (en) 2006-03-20 2007-09-27 Xtent, Inc. Apparatus and methods for deployment of linked prosthetic segments
ES2540059T3 (es) 2006-04-26 2015-07-08 Micell Technologies, Inc. Recubrimientos que contienen múltiples fármacos
US20070281117A1 (en) 2006-06-02 2007-12-06 Xtent, Inc. Use of plasma in formation of biodegradable stent coating
US20080269865A1 (en) * 2006-08-07 2008-10-30 Xtent, Inc. Custom Length Stent Apparatus
JP2010501499A (ja) * 2006-08-22 2010-01-21 ノバルティス アクチエンゲゼルシャフト 線維症の処置
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP2702993B1 (de) * 2006-09-13 2017-12-06 Elixir Medical Corporation Makrocyclische lactonverbindungen und verfahren zu deren verwendung
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) * 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
CN101522691B (zh) * 2006-11-27 2012-08-22 泰尔茂株式会社 O-烷基化雷帕霉素衍生物的制备方法及o-烷基化雷帕霉素衍生物
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
US20080199510A1 (en) 2007-02-20 2008-08-21 Xtent, Inc. Thermo-mechanically controlled implants and methods of use
US9888924B2 (en) 2007-03-06 2018-02-13 Covidien Lp Wound closure material
US8486132B2 (en) 2007-03-22 2013-07-16 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
JP5693228B2 (ja) * 2007-11-14 2015-04-01 バイオセンサーズ インターナショナル グループ、リミテッド 自動被覆装置および方法
US9101503B2 (en) 2008-03-06 2015-08-11 J.W. Medical Systems Ltd. Apparatus having variable strut length and methods of use
US20110098241A1 (en) * 2008-04-14 2011-04-28 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
MX2010011485A (es) 2008-04-17 2011-03-01 Micell Technologies Inc Stents que contienen capas bioadsorbibles.
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US20100055145A1 (en) * 2008-08-29 2010-03-04 Biosensors International Group Stent coatings for reducing late stent thrombosis
US8828071B2 (en) 2008-09-25 2014-09-09 Advanced Bifurcation Systems, Inc. Methods and systems for ostial stenting of a bifurcation
US12324756B2 (en) 2008-09-25 2025-06-10 Advanced Bifurcation Systems Inc. System and methods for treating a bifurcation
EP2344068B1 (de) 2008-09-25 2022-10-19 Advanced Bifurcation Systems Inc. Teilweise gekrimpter stent
US11298252B2 (en) 2008-09-25 2022-04-12 Advanced Bifurcation Systems Inc. Stent alignment during treatment of a bifurcation
US12076258B2 (en) 2008-09-25 2024-09-03 Advanced Bifurcation Systems Inc. Selective stent crimping
US8821562B2 (en) 2008-09-25 2014-09-02 Advanced Bifurcation Systems, Inc. Partially crimped stent
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
WO2010120552A2 (en) 2009-04-01 2010-10-21 Micell Technologies, Inc. Coated stents
US8381774B2 (en) * 2009-09-20 2013-02-26 Medtronic Vascular, Inc. Methods for loading a drug eluting medical device
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2011097103A1 (en) 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
CN103037816B (zh) 2010-03-24 2018-12-28 高级分支系统股份有限公司 用于处理分叉部的系统和方法
EP2549958A4 (de) 2010-03-24 2016-09-14 Advanced Bifurcation Systems Inc Verfahren und systeme zur behandlung einer bifurkation mit provisorischem seitenzweig-stenting
CA2794078A1 (en) 2010-03-24 2011-09-29 Advanced Bifurcation Systems, Inc. Stent alignment during treatment of a bifurcation
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2593039B1 (de) 2010-07-16 2022-11-30 Micell Technologies, Inc. Medizinische wirkstofffreisetzungsvorrichtung
WO2012017449A1 (en) 2010-08-04 2012-02-09 Meril Life Sciences Pvt. Ltd Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
US8632846B2 (en) * 2010-09-17 2014-01-21 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
CA2821905C (en) 2010-12-16 2018-07-10 Sumitomo Seika Chemicals Co., Ltd. Method for producing pseudopolyrotaxane aqueous dispersion
ES2552038T3 (es) 2010-12-16 2015-11-25 Sumitomo Seika Chemicals Co., Ltd. Método para la producción de un pseudopolirrotaxano
ES2596170T3 (es) * 2010-12-16 2017-01-05 Sumitomo Seika Chemicals Co., Ltd. Método para producir polirotaxano refinado
WO2012081429A1 (ja) 2010-12-16 2012-06-21 住友精化株式会社 擬ポリロタキサンの製造方法
EP3449879B1 (de) 2011-02-08 2020-09-23 Advanced Bifurcation Systems Inc. System zur behandlung einer bifurkation mit einem vollständig gecrimpten stent
CA2826760A1 (en) 2011-02-08 2012-08-16 Advanced Bifurcation Systems, Inc. Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use
CA2829854C (en) * 2011-03-14 2017-10-24 Sumitomo Seika Chemicals PROCESS FOR THE PRODUCTION OF HYDROPHILIC MODIFIED POLYROTAXANE
EP2687547B1 (de) * 2011-03-14 2017-02-08 Sumitomo Seika Chemicals CO. LTD. Polyrotaxanzusammensetzung
EP2687546B1 (de) * 2011-03-14 2015-09-23 Sumitomo Seika Chemicals CO. LTD. Herstellungsverfahren für pulverförmiges hydrophiles modifiziertes polyrotaxan
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2589383A1 (de) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP-subtypspezifisches Rapamycin-Analogon zur Verwendung bei der Behandlung von Erkrankungen
BR112014023572A2 (pt) 2012-03-23 2017-09-12 Univ Queensland método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes
KR102011170B1 (ko) * 2012-03-30 2019-08-14 우베 고산 가부시키가이샤 히드록시알킬화 폴리로탁산의 제조 방법
US9364273B2 (en) * 2012-08-15 2016-06-14 DePuy Synthes Products, Inc. Drug eluting surgical screw
CN103845290A (zh) 2012-12-03 2014-06-11 曼丽国际有限公司 Umirolimus及其衍生物用于治疗癌症的用途
ES2645951T3 (es) * 2013-01-22 2017-12-11 Biosensors International Group, Ltd. Síntesis a baja temperatura de derivados de rapamicina
CN105307597A (zh) * 2013-03-12 2016-02-03 脉胜医疗技术公司 可生物吸收的生物医学植入物
EP2968281B1 (de) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor-hemmer zur vorbeugung von darmpolypenwachstum
EP2972258B1 (de) 2013-03-15 2021-08-04 Biosensors International Group, Ltd. Reinigung von rapamycinderivaten
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
US20150073998A1 (en) 2013-09-09 2015-03-12 Apple Inc. Use of a Biometric Image in Online Commerce
CA2929181A1 (en) 2013-11-13 2015-05-21 Novartis Ag Mtor inhibitors for enhancing the immune response
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP4420663A3 (de) 2013-12-20 2024-10-30 Novartis AG Regulierbarer chimärer antigenrezeptor
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
EP3119425B1 (de) 2014-03-15 2020-09-23 Novartis AG Regulierbarer chimärer antigenrezeptor
SI3888674T1 (sl) 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
JP6300926B2 (ja) * 2014-07-08 2018-03-28 国立大学法人大阪大学 自己修復性を有する高分子材料及びその製造方法
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
EP3193915A1 (de) 2014-07-21 2017-07-26 Novartis AG Kombinationen aus niedrigen, immunfördernden dosen von mtor-inhibitoren und cars
EP4205749A1 (de) 2014-07-31 2023-07-05 Novartis AG Subset-optimierte chimäre antigenrezeptorhaltige zellen
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
RU2020117196A (ru) 2014-08-19 2020-10-15 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
CN113620978A (zh) 2014-09-11 2021-11-09 加利福尼亚大学董事会 mTORC1抑制剂
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3280795B1 (de) 2015-04-07 2021-03-24 Novartis AG Kombination von chimärer antigen rezeptor therapie und amino pyrimidin derivaten
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (de) 2015-04-23 2018-02-28 Novartis AG Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker
WO2016185443A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
EP3373927A1 (de) 2015-11-11 2018-09-19 Novartis AG Verwendungen von myostatin-antagonisten, kombinationen damit und verwendungen davon
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
WO2018096402A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3624863B1 (de) 2017-05-15 2021-04-14 C.R. Bard, Inc. Medizinische vorrichtung mit wirkstofffreisetzender beschichtung und zwischenschicht
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
MX2020011564A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina unidos a c26 como inhibidores de mtor.
EP3788369A1 (de) 2018-05-01 2021-03-10 Novartis Ag Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses
HRP20230488T1 (hr) 2018-05-01 2023-08-04 Revolution Medicines, Inc. C40-, C28- I C-32-VEZANI ANALOZI RAPAMICINA KAO INHIBITORI mTOR
BR112020025283A2 (pt) 2018-06-15 2021-03-09 Navitor Pharmaceuticals, Inc. Análogos de rapamicina e usos dos mesmos
CN113226389B (zh) 2018-11-14 2022-11-08 乐通公司 在经改性设备表面上具有药物洗脱涂层的医疗设备
EA202191983A1 (ru) * 2019-01-22 2021-12-01 Аеовиан Фармасьютикалз, Инк. МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ
WO2020157044A1 (en) * 2019-01-30 2020-08-06 Biotronik Ag Covered stent for local drug delivery
JP7487228B2 (ja) 2019-04-08 2024-05-20 バード・ペリフェラル・バスキュラー・インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
US11517457B2 (en) * 2019-07-03 2022-12-06 Abbott Cardiovascular Systems Inc. Intravascular stent
AU2020397938A1 (en) * 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
CN116102576B (zh) * 2021-11-09 2025-08-29 上海博畅医疗科技有限公司 一种优美莫司晶体的制造方法及其应用
US12539305B2 (en) 2022-05-25 2026-02-03 Revolution Medicines, Inc. Methods of treating cancer with an mTOR inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127248A (en) * 1872-05-28 Improvement in sash-holders
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
NZ277498A (en) * 1993-12-17 1998-03-25 Novartis Ag Rapamycin derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
KR100400620B1 (ko) 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
ES2219388T3 (es) * 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
US20020013335A1 (en) 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same

Also Published As

Publication number Publication date
EP1689754A1 (de) 2006-08-16
EP1852437A2 (de) 2007-11-07
HK1097828A1 (en) 2007-07-06
US20050131008A1 (en) 2005-06-16
EP1689754B1 (de) 2007-08-08
DE602004008105T2 (de) 2008-04-30
US7220755B2 (en) 2007-05-22
DE602004008105D1 (de) 2007-09-20
EP1852437B1 (de) 2014-09-17
WO2005047295A1 (en) 2005-05-26
EP1852437A3 (de) 2008-03-12
ES2516692T3 (es) 2014-10-31
US20050101624A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
ATE369372T1 (de) 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen
DE602004000926D1 (de) Antimikrobielle Glaszusammensetzung und diese enthaltende antimikrobielle Polymerzusammensetzung
DE602004023342D1 (de) Siliconzusammensetzung und diese enthaltendes Papierbehandlungsmittel
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60232981D1 (de) 3-phenoxy-4-pyridazinolderivat und dieses enthaltende herbizide zusammensetzung
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
FIC20190031I1 (fi) Rifamysiini SV
SE0302811D0 (sv) Novel compounds
DE60317799D1 (de) Antimikrobielle zusammensetzung und anwendungsverfahren
ATE463264T1 (de) Absorbierende polymerzusammensetzungen, medizinische artikeln und verfahren
IL160051A0 (en) Ecteinascidin derivatives and pharmaceutical compositions containing the same
DE60232701D1 (de) Polymerverbindung enthaltend Siliciumestergruppen und diese enthaltende Zusammensetzungen
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
CL2004001678A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica; y uso de los compuestos como agentes bacterianos.
DK1557415T3 (da) Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
SE0302139D0 (sv) Novel compounds
ATE515262T1 (de) Verwendung von parthenolid-derivaten als antileukämische und zytotoxische mittel
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
DE60231209D1 (de) Antithrombotische zusammensetzungen und diese enthaltende medizinische instrumente
SE0003476D0 (sv) Compounds
SE0303280D0 (sv) Novel compounds
DE60318590D1 (de) Vernetzbare acrylkautschukzusammensetzung und formkörper
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties